Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the risk of progression by 30% compared to Sanofi’s Aubagio.
The drug, a once-monthly injection that patients can administer themselves at home reduced relapse rates by 50.5% and 58.5% in trials compared with Sanofi’s, daily pill Aubagio.
The findings were announced at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
